Literature DB >> 14660644

Aspartate 345 of the dopamine transporter is critical for conformational changes in substrate translocation and cocaine binding.

Nianhang Chen1, Judy Rickey, Janet L Berfield, Maarten E A Reith.   

Abstract

The present study elucidated the role of aspartate 345, a residue conserved in the third intracellular loop of all Na+/Cl(-)-dependent neurotransmitter transporters, in conformational changes of the dopamine (DA) transporter. Asparagine substitution (D345N) resulted in near normal transporter expression on the cell surface but caused extremely low Vmax and Km values for DA uptake, converted the inhibitory effect of Zn2+ on DA uptake to a stimulatory one, and eliminated reverse transport. The cocaine-like inhibitor 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane or the selective DA transporter inhibitor GBR12935 bound to D345N with a normal affinity and still inhibited DA uptake potently. However, the mutation reduced the binding capacity of the surface transporter for these two inhibitors by 90% or more. Moreover, the binding activity of D345N can be significantly improved by Zn2+ but not by Na+. These results are consistent with a defect in reorientation of the substrate-binding site to the extracellular side, leading to a loss of the outward-facing conformational state where external DA binds to initiate uptake and the inhibitors bind to initiate uptake inhibition. Alanine or glutamate substitution produced a similar phenotype, suggesting that both the negative charge and the residue volume at position 345 are vital. Furthermore, in intact cells, cocaine potentiated the reaction of the membrane-impermeant sulfhydryl reagent methanethiosulfonate ethyltrimethylammonium with the extracellularly located endogenous cysteines of D345N but not those of wild type, and this potentiation was blocked upon K+ substitution for Na+. Thus, cocaine binding to D345N likely induces a different and Na(+)-dependent conformational change, which may contribute to its Na(+)-dependent uptake inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660644     DOI: 10.1074/jbc.M306294200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

Review 1.  Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters.

Authors:  Christopher K Surratt; Okechukwu T Ukairo; Suneetha Ramanujapuram
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

2.  An N-terminal threonine mutation produces an efflux-favorable, sodium-primed conformation of the human dopamine transporter.

Authors:  Rheaclare Fraser; Yongyue Chen; Bipasha Guptaroy; Kathryn D Luderman; Stephanie L Stokes; Asim Beg; Louis J DeFelice; Margaret E Gnegy
Journal:  Mol Pharmacol       Date:  2014-04-21       Impact factor: 4.436

3.  Dopamine transporter oligomerization: impact of combining protomers with differential cocaine analog binding affinities.

Authors:  Juan Zhen; Tamara Antonio; Shu-Yuan Cheng; Solav Ali; Kymry T Jones; Maarten E A Reith
Journal:  J Neurochem       Date:  2015-01-26       Impact factor: 5.372

Review 4.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

5.  Interaction of catechol and non-catechol substrates with externally or internally facing dopamine transporters.

Authors:  Ying-Jian Liang; Juan Zhen; Nianhang Chen; Maarten E A Reith
Journal:  J Neurochem       Date:  2009-03-11       Impact factor: 5.372

6.  The N terminus of monoamine transporters is a lever required for the action of amphetamines.

Authors:  Sonja Sucic; Stefan Dallinger; Barbara Zdrazil; René Weissensteiner; Trine N Jørgensen; Marion Holy; Oliver Kudlacek; Stefan Seidel; Joo Hwan Cha; Ulrik Gether; Amy H Newman; Gerhard F Ecker; Michael Freissmuth; Harald H Sitte
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

7.  Conformational changes in dopamine transporter intracellular regions upon cocaine binding and dopamine translocation.

Authors:  Yvette Dehnes; Jufang Shan; Thijs Beuming; Lei Shi; Harel Weinstein; Jonathan A Javitch
Journal:  Neurochem Int       Date:  2014-02-24       Impact factor: 3.921

8.  Molecular basis for zinc transporter 1 action as an endogenous inhibitor of L-type calcium channels.

Authors:  Shiri Levy; Ofer Beharier; Yoram Etzion; Merav Mor; Liat Buzaglo; Lior Shaltiel; Levi A Gheber; Joy Kahn; Anthony J Muslin; Amos Katz; Daniel Gitler; Arie Moran
Journal:  J Biol Chem       Date:  2009-09-18       Impact factor: 5.157

9.  Conserved glutamate residues Glu-343 and Glu-519 provide mechanistic insights into cation/nucleoside cotransport by human concentrative nucleoside transporter hCNT3.

Authors:  Melissa D Slugoski; Kyla M Smith; Amy M L Ng; Sylvia Y M Yao; Edward Karpinski; Carol E Cass; Stephen A Baldwin; James D Young
Journal:  J Biol Chem       Date:  2009-04-20       Impact factor: 5.157

10.  A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation.

Authors:  Bipasha Guptaroy; Minjia Zhang; Erica Bowton; Francesca Binda; Lei Shi; Harel Weinstein; Aurelio Galli; Jonathan A Javitch; Richard R Neubig; Margaret E Gnegy
Journal:  Mol Pharmacol       Date:  2008-12-19       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.